MedKoo Cat#: 412400 (free base) | Name: Carsatrin (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carsatrin is purinylpiperazine derivative patented by Ortho Pharmaceutical Corp. as cardiotonic and antiarrhythmic. Carsatrin acts as positive inotropic agent that increases twitch tension and prolongs the action potential (AP) duration of ventricular muscle without affecting the Na+,K+-ATPase, adenylyl cyclase, phosphodiesterase isozymes, or cardiac myofilaments. Carsatrin’s positive inotropic effect can be prevented by tetrodotoxin but not by the adrenergic antagonists timolol, yohimbine, or prazosin

Chemical Structure

Carsatrin (free base)
Carsatrin (free base)
CAS#125363-87-3

Theoretical Analysis

MedKoo Cat#: 412400 (free base)

Name: Carsatrin (free base)

CAS#: 125363-87-3

Chemical Formula: C25H26F2N6OS

Exact Mass: 496.1857

Molecular Weight: 496.58

Elemental Analysis: C, 60.47; H, 5.28; F, 7.65; N, 16.92; O, 3.22; S, 6.46

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
412400 (free base) 132199-13-4 (salt)
Synonym
Carsatrin; UNII-2E3S34L69I
IUPAC/Chemical Name
1-Piperazineethanol, 4-(bis(4-fluorophenyl)methyl)-alpha-((1H-purin-6-ylthio)methyl)-
InChi Key
JOMBZLFCXNSKEQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H26F2N6OS/c26-19-5-1-17(2-6-19)23(18-3-7-20(27)8-4-18)33-11-9-32(10-12-33)13-21(34)14-35-25-22-24(29-15-28-22)30-16-31-25/h1-8,15-16,21,23,34H,9-14H2,(H,28,29,30,31)
SMILES Code
OC(CSC1=C2N=CN=C2N=CN1)CN3CCN(C(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 496.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Press JB, Falotico R, Hajos ZG, Sawyers RA, Kanojia RM, Williams L, Haertlein B, Kauffman JA, Lakas-Weiss C, Salata JJ. Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes. J Med Chem. 1992 Nov 27;35(24):4509-15. doi: 10.1021/jm00102a001. PMID: 1335073. 2: Tsushima RG, Kelly JE, Salata JJ, Liberty KN, Wasserstrom JA. Modification of cardiac Na(+) current by RWJ 24517 and its enantiomers in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):845-55. PMID: 10525108. 3: Krafte DS, Davison K, Dugrenier N, Estep K, Josef K, Barchi RL, Kallen RG, Silver PJ, Ezrin AM. Pharmacological modulation of human cardiac Na+ channels. Eur J Pharmacol. 1994 Feb 15;266(3):245-54. doi: 10.1016/0922-4106(94)90133-3. PMID: 8174607. 4: Kawamura A, Wahler GM, Solaro RJ. RWJ-24517, a positive inotropic agent, has novel effects on action potentials in guinea pig myocardium. J Cardiovasc Pharmacol. 1993 Oct;22(4):519-25. doi: 10.1097/00005344-199310000-00003. PMID: 7505352.